Bio recap

/ / Day Trading

AERI FDA Approval +5%; Axovant AXGT offering

Aerie Pharmaceuticals, Inc.(NASDAQ:AERI) announced after-hours Tuesday that the FDA approved Rocklatan 0.02%/0.005% to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Shares closed Wednesday up 5% to $47.97.

Akari Therapeutics, Plc (Nasdaq: AKTX) shares, which were in nano-cap territory prior to today, closed up 224% to $5.90 on the back of news that it will commence a pivotal trial for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), in 4Q 2019, following pre-IND discussions with the FDA.

Axovant Sciences (Nasdaq: AXGT) announced that it has commenced an underwritten public offering of its common shares. Shares are trading down 10% to $1.58 after hours.


Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume

ADVANCERS:

Conatus Pharmaceuticals Inc. (CNAT): $2.89; +26%.

Diffusion Pharmaceuticals Inc. (DFFN): $6.00; +23%.

Nabriva Therapeutics plc (NBRV): $2.81; +16%.

Curis, Inc. (CRIS): $1.29; +14%.

NuCana plc (NCNA): $15.08; +13%.

DECLINERS:

INSYS Therapeutics, Inc. (INSY): $4.25; -25%.

Amphastar Pharmaceuticals, Inc. (AMPH): $20.68; -14%.

Seelos Therapeutics, Inc. (SEEL): $3.30; -14%.